胸腔置管引流联合腔内注射尿激酶在包裹性胸腔积液的临床应用价值观察

目的：探讨胸腔置管引流联合腔内注射尿激酶治疗在包裹性胸腔积液的临床应用价值。方法：将100例胸腔积液患者按随机数字表法分为研究组和对照组，每组50例。研究组给予胸腔置管引流联合腔内注射尿激酶治疗，对照组给予常规反复胸腔穿刺抽液治疗，比较两组在疗效、住院天数和治疗费用等方面的差异。结果：研究组治疗有效率为96.0%，高于对照组的82.0%（χ2=5.005，P=0.025）；研究组疗效也高于对照组，差异有统计学意义（Z=2.842，P=0.004）；研究组胸腔积液消失时间短于对照组，肺功能中FEV1%和FVC%均高于对照组，住院时间短于对照组，差异均有统计学意义（P〈0.05）；两组的住院费用比较差异无统计学意义（P〉0.05）。结论：胸腔置管引流联合腔内注射尿激酶是一种安全简便、疗效好、适合基层医院应用的治疗包裹性胸腔积液的方法。

Observation on Clinical Application Value of Intracavitary Urokinase Injection Combined with Thoracic Drainage by Tube

Objective：To investigate clinical application value of intracavitary urokinase injection combined with thoracic drainage by tube.Method：100 patients of pleural effusion were divided into the study group（n=50）and the control group（n=50）. Intracavitary urokinase injection combined with thoracic drainage by tube were adopted in the study group. While routinely repeated thoracentesis treatment was used to draw the pleural effusion in the control group. The two groups’difference on curative effect,hospital day ,treatment costs and so on were analyzed.Result：The effective rate of the study group was 96.0%,and was higher than the control group’s 82.0%（ χ2=5.005,P=0.025）,the team effectiveness was higher than the control group,the difference was statistically significant（Z=2.842,P=0.004）. In the study group,pulmonary function included FEV1%and FVC%were higher than that in the control group,the vanish time of pleural effusion was shorter than that in the control group,the hospital day was shorter than that in the control group,the differences were statistically significant（P〈0.05）. And there was no difference in cost of hospitalization between the two groups（P〉0.05）.Conclusion：Intracavitary urokinase injection combined with thoracic drainage by tube is a treatment of safety,convenience,nice curative effect and so on. So it is a good method suited for the primary hospitals to apply.